Oncology Institute Company Top Insiders

TOI Stock  USD 0.16  0.01  5.88%   
Oncology Institute's insiders are aggressively selling. The analysis of insiders' sentiment of trading Oncology Institute stock suggests that almost all insiders are panicking at this time. Oncology Institute employs about 800 people. The company is managed by 19 executives with a total tenure of roughly 1867 years, averaging almost 98.0 years of service per executive, having 42.11 employees per reported executive.

Oncology Institute's Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-01-29Havencrest Healthcare PartnersDisposed 8637 @ 2.12View
2024-01-26Havencrest Healthcare PartnersDisposed 6979 @ 2.14View
2024-01-24Havencrest Healthcare PartnersDisposed 24915 @ 2.3View
2024-01-22Havencrest Healthcare PartnersDisposed 10263 @ 2.12View
2024-01-19Havencrest Healthcare PartnersDisposed 11986 @ 2.13View
Monitoring Oncology Institute's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Oncology Institute. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.

Oncology Institute Management Team Effectiveness

The company has Return on Asset of (0.1942) % which means that on every $100 spent on assets, it lost $0.1942. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.2559) %, meaning that it generated no profit with money invested by stockholders. Oncology Institute's management efficiency ratios could be used to measure how well Oncology Institute manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.47. The current Return On Capital Employed is estimated to decrease to -0.46. As of now, Oncology Institute's Asset Turnover is decreasing as compared to previous years.
The Oncology Institute's current Net Income Applicable To Common Shares is estimated to increase to about 64.3 K, while Common Stock Shares Outstanding is projected to decrease to under 68.4 M.

Oncology Institute Workforce Comparison

Oncology Institute is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 676,400. Oncology Institute adds roughly 800 in number of employees claiming only tiny portion of equities under Health Care industry.

Oncology Institute Profit Margins

The company has Net Profit Margin of (0.2) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.17) %, which entails that for every $100 of revenue, it lost $0.17.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.220.1837
Fairly Up
Slightly volatile

Oncology Institute Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oncology Institute insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oncology Institute's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Oncology Institute insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Oncology Institute Notable Stakeholders

An Oncology Institute stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Oncology Institute often face trade-offs trying to please all of them. Oncology Institute's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Oncology Institute's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Julie KorinkeDirector CommunicationsProfile
FACHE MDChief OfficerProfile
Mark EsqGeneral CounselProfile
Rob CarterSenior FinanceProfile
Bradford HivelyCEO DirectorProfile
Rakesh MBADirector TechnologyProfile
Laura SzitarChief OfficerProfile
Richard BaraschExecutive BoardProfile
Jeremy MBAChief OfficerProfile
Diona CPAPrincipal OfficerProfile
MBA JDSenior ComplianceProfile
FACHE MBAPresidentProfile
Philip RegerChief OfficerProfile
MD MBAChief OfficerProfile
Hilda MBAFounder OfficerProfile
Mihir CPAChief OfficerProfile
Jordan McInerneyChief OfficerProfile
Richy MDFounder OfficerProfile
FACS MDChief PracticeProfile

About Oncology Institute Management Performance

The success or failure of an entity such as Oncology Institute often depends on how effective the management is. Oncology Institute management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Oncology management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Oncology management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.45)(0.47)
Return On Capital Employed(0.44)(0.46)
Return On Assets(0.40)(0.38)
Return On Equity(1.46)(1.38)

Oncology Institute Workforce Analysis

Traditionally, organizations such as Oncology Institute use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Oncology Institute within its industry.

Oncology Institute Manpower Efficiency

Return on Oncology Institute Manpower

Revenue Per Employee405.3K
Revenue Per Executive17.1M
Net Loss Per Employee103.8K
Net Loss Per Executive4.4M
Working Capital Per Employee135.9K
Working Capital Per Executive5.7M

Complementary Tools for Oncology Stock analysis

When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Transaction History
View history of all your transactions and understand their impact on performance
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine